AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by Pfizer. Now, he thinks that ...

Learn more about whether IDEAYA Biosciences, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing.

1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.